VIVUS Inc. is Today's Focus Stock on MicroStockProfit.com


DALLAS, June 28, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses you need to know to make an educated investment decision.

Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.

The full report is available at: www.microstockprofit.com/lp/VVUS

VVUS's recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, VVUS is trading near its lower Bollinger Band. This suggests that the stock price is low relative to its recent price action.

VIVUS Inc. (VVUS) focuses on the development and commercialization of therapeutic products. The Company's product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity, for which the two of the phase III studies are in process and one phase III study has been completed; Qnexa for treating diabetes, for which a one-year phase II study has been completed; Avanafil, is being developed for the treatment of erectile dysfunction, for which phase III studies are in process; and Luramist, which is being developed to treat hypoactive sexual desire disorder in women, for which a phase II study has been completed. 

Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS

In the report, the analyst notes:

"Product revenues from the sale of MUSE in the first quarter of 2010 were $1.6 million as compared to $1.2 million in the first quarter of 2009 due to the increase in number of units sold in 2010 as compared to last year. Total revenue for the first quarter of 2010 was $1.7 million as compared to $22.2 million for the first quarter of 2009.  

"VVUS recently announced that data from a previously reported phase II study evaluating the safety and efficacy of the investigational drug Qnexa(R) for the treatment of obstructive sleep apnea (OSA) were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies (APSS)."

To read the entire report visit: www.microstockprofit.com/lp/VVUS

See what investors are saying about VVUS at penny stock forum

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.



            

Contact Data